Drug Profile
Research programme: systemic lupus erythematosus therapy - La Jolla/Neurome
Alternative Names: Systemic lupus erythematosus research programme - La Jolla/NeuromeLatest Information Update: 25 Aug 2022
Price :
$50
*
At a glance
- Originator La Jolla Pharmaceutical Company; Neurome
- Developer La Jolla Pharmaceutical Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Systemic lupus erythematosus